Sign in
Taking people in United StatesPhase 2

Tests tirzepatide effects on muscle and blood vessels in older adults with obesity

Tests tirzepatide on muscle and blood vessel health in older adults with obesity.

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Registry title
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Apr 2026
Expected to end
1 Jun 2027
Type of study
Interventional
Treatments tested
  • Tirzepatide
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and postmenopausal women aged 50 or older with obesity but without type 2 diabetes. It studies how 6 months of tirzepatide affects muscle and vascular function.

Age
50 years or older
Sex
Men and postmenopausal women
Disease stage
BMI of 30 kg/m² or more (but under 40). Untreated HbA1c below 6.5% (48 mmol/mol).
Earlier treatment
Cannot be taking any GLP-1 receptor agonist medicine at the same time.
Biomarker or test result
Untreated HbA1c below 6.5% (48 mmol/mol) at baseline. AST not above 33 U/L and ALT not above 36 U/L.

Main reasons for not taking part

  • Type 2 diabetes (using glucose-lowering medicines or HbA1c of 6.5% (48 mmol/mol) or more)
  • BMI of 40 kg/m² or more
  • Moderate to severe reflux disease (GERD)
  • Chronic kidney disease stage 4
  • Active pregnancy

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Men and postmenopausal women aged 50 years or older
  • Body Mass Index (BMI) ≥30 kg/m²
  • Untreated HbA1c <6.5% at baseline
  • Willingness and ability to comply with all study procedures, including fasting requirements for certain visits
  • Able to provide informed consent and participate in all study assessments

Who cannot take part

  • Concomitant treatment with GLP-1 receptor agonist therapy
  • Moderate to severe gastroesophageal reflux disease based on patient history
  • Chronic Kidney Disease (CKD) Stage 4
  • Personal or family history of medullary thyroid carcinoma
  • Personal or family history of multiple endocrine neoplasia type 2 syndrome
  • Personal history of gastroparesis
  • Personal history of diabetic retinopathy
  • Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients
  • Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies
  • Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%
  • Aspartate aminotransferase (AST) > 33 U/L or alanine aminotransferase (ALT) > 36 U/L
  • Body Mass Index (BMI) ≥ 40 kg/m²
  • Inability to comply with the treatment protocol or to understand the consent form
  • Active pregnancy

Where in United States

  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Shreya RaoTaking people

About the trial

What the trial wants to find out

Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.

The group in the trial

  • TirzepatideTreatment being tested

    Tirzepatide self-administered once weekly by subcutaneous injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults
Plain-language title
Tests tirzepatide effects on muscle and blood vessels in older adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 April 2026